The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C.
about
Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning?Current status of novel antifibrotic therapies in patients with chronic liver diseaseRole of NADPH oxidases in liver fibrosis.Translation of Angiotensin-Converting Enzyme 2 upon Liver- and Lung-Targeted Delivery of Optimized Chemically Modified mRNAMedical therapy of stricturing Crohn's disease: what the gut can learn from other organs - a systematic review.Susceptibility and gene interaction study of the angiotensin II type 1 receptor (AGTR1) gene polymorphisms with non-alcoholic fatty liver disease in a multi-ethnic population.The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort.Renin-angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review.Effects of Angiotensin Converting Enzyme Inhibitors on Liver Fibrosis in HIV and Hepatitis C CoinfectionEffects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis CTelmisartan attenuates hepatic fibrosis in bile duct-ligated rats.The role of the renin-angiotensin system in liver fibrosis.Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options.Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis.New therapies for hepatic fibrosis.Novel treatment options for portal hypertension.Evolving paradigm of treatment for autoimmune hepatitis.New Developments on the Treatment of Liver Fibrosis.Targeting Hepatic Fibrosis in Autoimmune Hepatitis.Renin angiotensin system in liver diseases: Friend or foe?Review article: next-generation transformative advances in the pathogenesis and management of autoimmune hepatitis.Therapeutic effect of renin angiotensin system inhibitors on liver fibrosis.Effects of Azilsartan, Aliskiren or their Combination on High Fat Diet-induced Non-alcoholic Liver Disease Model in Rats.Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment.Lack of efficacy of mTOR inhibitors and ACE pathway inhibitors as antifibrotic agents in evolving and established fibrosis in Mdr2⁻/⁻ mice.Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma.Clinical application of angiotensin receptor blockers in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis.Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension.
P2860
Q26829503-5F9A8B6C-FB86-4795-B51C-2E3968E264ACQ30473375-A8E50DC8-C6CC-4ECF-8903-A1AD98E18AD4Q33632736-ED08FE38-B1FC-48AD-AEC9-CA9745A39E6CQ33652543-8400ECDA-CA3E-48DA-B876-B4FC25F3DD94Q34504710-0F6BC28E-FEDB-4C16-A3C2-055AF510FA96Q34618881-90CB98A5-47F0-4DAC-8FB4-44DDF1B8A688Q35124395-3855CE4E-F14B-4F4E-941B-B8AA0EF45E6EQ35931751-8731328B-A8EF-48CD-8F9D-3F83206838E5Q36410515-FD6BBC7D-723D-4DE6-8C9A-95B9682BA7BCQ37391823-3FD2840E-AA46-4FB9-8ADE-021EDD842AE8Q37727167-D5E0DB02-D30B-4D0A-B6A4-C201D5F19ADDQ37867350-AB74547C-FDBF-4BC5-92D7-0170516BED41Q38006726-E73FE62D-CE7E-41CB-8FBF-57CCE2677B57Q38175465-ACDD3929-817C-4975-ACEB-B842600AAD06Q38553309-9368DC03-F5A7-4F76-AF35-6EB0C261F8FDQ38680437-35218060-ADBE-42B3-A55B-8489D2232EFBQ38730872-15F03A85-BD18-4723-8028-C7E221DD38E1Q38873303-A209118A-6F5B-4A4F-A9EF-9A6DD1ABC5D9Q38902371-708BC7F6-4F32-4576-9F30-E01B1C2251A7Q39360840-87803B57-2855-43DA-816B-EB23D9383EF2Q40044046-D73F06AC-F6EF-4356-9E11-F5A286F3DA34Q40743246-3B0039BF-1525-4CD3-B9C0-A54B5D197C09Q42354239-8517BF5A-9231-435E-BA4C-EFFA770E685DQ42972424-7EDBB764-86D7-43CD-AA42-3F608A131B0BQ46933191-064E5B63-3400-450B-BE46-5512849A17ABQ47106953-797DDA5D-C10C-4732-A2A2-8D587E9CB267Q55008612-F7649504-370E-4278-9AE4-BCAB7FF6EB83Q55363090-E9B0D6AE-AD53-4876-A0B0-16A8461D5B82
P2860
The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C.
@ast
The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C.
@en
type
label
The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C.
@ast
The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C.
@en
prefLabel
The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C.
@ast
The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C.
@en
P2093
P2860
P1433
P1476
The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C.
@en
P2093
Atul K Bhan
Barham K Abu Dayyeh
Joseph Misdraji
Kathleen E Corey
Nirali Shah
P2860
P304
P356
10.1111/J.1478-3231.2009.01973.X
P577
2009-02-09T00:00:00Z